MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds related to
common stock...
$126,404K
Proceeds from employee
stock purchase plan...
$2,676K
Net cash provided by
financing activities
$128,733K
Canceled cashflow
$347K
Net decrease in
cash, cash...
-$55,333K
Canceled cashflow
$128,733K
Impairment of long-lived
assets
$44,611K
Stock-based compensation
expense
$25,464K
Change in the estimated
fair value of...
$14,750K
Change in the estimated
fair value of success...
$14,682K
Depreciation
$12,750K
Non-cash expense for
operating lease...
$9,171K
Prepaid expenses and
other assets
-$1,165K
Proceeds from maturities
of marketable...
$46,561K
Proceeds from disposal of
assets
$1,432K
Proceeds (principal
payments), net for tenant...
-$347K
Net cash used in
operating activities
-$143,828K
Canceled cashflow
$122,593K
Net cash provided by
(used in) investing...
-$40,238K
Canceled cashflow
$47,993K
Net loss
-$244,166K
Other non-cash items,
net
$10,976K
Accrued expenses and
other liabilities
-$4,737K
Accounts payable
-$3,545K
Operating lease
right-of-use assets and...
$2,997K
Purchases of marketable
securities
$87,293K
Purchases of property and
equipment
$938K
Back
Back
Cash Flow
source: myfinsight.com
Sana Biotechnology, Inc. (SANA)
Sana Biotechnology, Inc. (SANA)